Fast Five Quiz: Rheumatoid Arthritis Management

Herbert S. Diamond, MD


June 10, 2020

A 2011 meta-analysis of 2183 patients by Thompson and colleagues found that newly diagnosed, DMARD-naive patients did not have an increased risk of serious infection or malignancy when treated with TNF inhibitors. Similarly, a large-scale, prospective study by Lunt and colleagues of 12,672 patients starting to receive anti-TNF therapy and 3522 biologic-naive patients receiving conventional DMARDs found no associated increased risk of mortality in patients receiving TNF inhibitors compared with patients receiving conventional DMARDs.

A 2011 systematic review and meta-analysis by Mariette and colleagues of 2039 full-text papers and 1979 abstracts from conferences found that TNF inhibitors do not appear to increase risk of malignancy, specifically lymphoma; however, TNF inhibitors were associated with an increased risk of melanoma.

Learn more about side effects and risks associated with pharmacologic therapy for RA.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.